SCHEMBL1032862

SCHEMBL1032862

Cc1cc(C)c(C(=O)CC(C)(C)C(=O)CP)c(C)c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ LMNA P02545 5/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ MAPT P10636 2/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ MEN1 O00255 3/20 0.38
▸ KMT2A Q03164 3/20 0.38
▸ HPGD P15428 2/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ GAA P10253 2/20 0.36
▸ POLB P06746 2/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.33
▸ MCOLN3 Q8TDD5 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ ELANE P08246 1/20 0.32
▸ NR2F2 P24468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5995538 0.72 HPGD (0.36) L3MBTL1KDM4ELMNAALDH1A1MAPT
SCHEMBL1698306 0.72 L3MBTL1 (0.44) L3MBTL1KDM4ELMNAALDH1A1MAPT
SCHEMBL5997078 0.71 ALDH1A1 (0.44) L3MBTL1KDM4ELMNAALDH1A1MAPT
SCHEMBL5043808 0.70 LMNA (0.41) L3MBTL1KDM4ELMNAALDH1A1MAPT
SCHEMBL11053483 0.69 MEN1 (0.51) L3MBTL1KDM4ELMNAALDH1A1MAPT
SCHEMBL4020410 0.69 ALDH1A1 (0.40) L3MBTL1KDM4ELMNAALDH1A1MAPT
SCHEMBL11210247 0.68 MEN1 (0.50) L3MBTL1KDM4ELMNAALDH1A1MAPT
SCHEMBL8412767 0.68 ALDH1A1 (0.47) L3MBTL1KDM4ELMNAALDH1A1MAPT
SCHEMBL8412772 0.68 ALDH1A1 (0.47) L3MBTL1KDM4ELMNAALDH1A1MAPT
SCHEMBL6907962 0.67 MEN1 (0.43) L3MBTL1KDM4ELMNAALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1814891-B1 BISACYLPHOSPHANES AND THEIR USE AS PHOTOINITIATORS; PROCESS FOR PREPARING ACYLPHOSPHANES BASF SE (DE) 2011-01-26 — — EP disclosed
US-7687657-B2 Process for preparing acylphosphanes and derivatives thereof CIBA SPECIALITY CHEMICALS CORPORATION (US) 2010-03-30 — — US disclosed
US-20080004464-A1 Process for Preparing Acylphosphanes and Derivatives Thereof IGM GROUP B.V. (NL) 2008-01-03 — — US disclosed
EP-1814891-A1 PROCESS FOR PREPARING ACYLPHOSPHANES AND DERIVATIVES THEREOF Ciba Specialty Chemicals Holding Inc. (CH) 2007-08-08 — — EP disclosed
WO-2006056541-A1 PROCESS FOR PREPARING ACYLPHOSPHANES AND DERIVATIVES THEREOF CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2006-06-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004464-A1 Process for Preparing Acylphosphanes and Derivatives Thereof ME2, ME3, MEP1A L3MBTL1 1140/4885KDM4E 2950/4885LMNA 1081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback